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Abstract The aim of the present study was to investigate
the morphology and function of a drug eluting metallic
porous surface produced by the immobilization of poly
lactide-co-glycolide microspheres bearing dexamethasone
onto plasma electrolytically oxidized Ti–6Al–7Nb medical
alloy. Spheres of 20 lm diameter were produced by an oil-
in-water emulsion/solvent evaporation method and ther-
mally immobilized onto titanium discs. The scanning
electron microscopy investigations revealed that the size
distribution and morphology of the attached spheres had
not changed signiﬁcantly. The drug release proﬁles fol-
lowing degradation in phosphate buffered saline for 1000 h
showed that, upon immobilisation, the spheres maintained
a sustained release, with a triphasic proﬁle similar to the
non-attached system. The only signiﬁcant change was an
increased release rate during the ﬁrst 100 h. This difference
was attributed to the effect of thermal attachment of the
spheres to the surface.
1 Introduction
During 2007, there were more than 150,000 patients
requiring total or partial joint arthroplasty in the United
Kingdom alone [1]. At the same time, 13,000 patients
required revision surgery, many of these due to septic or
aseptic implant loosening. One way to reduce this pro-
portion is to improve implant ﬁxation. Previous work has
been undertaken to control cellular activity by the gener-
ation of micro- or nanotexture onto the surface of metallic
implants [2]. There is hope that drug eluting medical
combination devices may afford even greater ﬁxation by
means of triggering speciﬁc cellular interactions next to
providing additional biofunctionalities (e.g. antibacterial
activity).
Poly (lactide-co-glycolide) (PLGA) has been studied
since the 1980s [3] as a carrier for sustained drug release. It
is known to degrade in water over time via hydrolytic
ﬁssion [4], and the end products of this reaction are lactic
and glycolic acid. Both of these chemicals are readily
soluble in water and are excreted by mammals. These
properties make PLGA a very attractive implant material,
as no surgery is needed to remove the implant after its
function is no longer required.
PLGA is known to show good chemical biocompati-
bility in animal studies due to a limited inﬂammatory
response [5, 6]. As a result, PLGA has been used for many
years as an implantable material, capable of being degra-
ded in situ and require no further intervention for removal.
A common example of this is its use as restorable sutures
[7]. The degradation is controlled by local pH and polymer
hydrophilicity. Some papers report an unusually large
amount of inﬂammation from PLGA implants [8], usually
attributed to the falling pH during polymer degradation. In
an attempt to reduce this effect, research has been per-
formed on modiﬁcation of the PLGA matrix by the
incorporation of basic salts [9, 10].
As a semicrystalline polymer, PLGA can also incorpo-
rate small hydrophobic molecules into its structure and
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tion by a combination of diffusion and degradation [11]. It
can also be processed to encapsulate small aqueous drop-
lets of hydrophilic drugs [12], or as a suspension of dry
drug particles [13, 14]. The last two techniques are suitable
for delivering proteins, whilst all three are suitable for
delivery of lower molecular weight drugs. Whilst micro-
spheres are usually used to deliver drugs to a single site of
action, nanospheres have been used for drug delivery in
cases needing considerable diffusion, such as intraocularly
[15] or as an aerosol [16].
PLGA can be used to deliver drugs in the form of ﬁlms
or microparticles. PLGA ﬁlms can be used on metallic
surfaces to some effect, particularly in stents where sus-
tained delivery of drugs is critical in preventing restenosis
[17]. However, this type of delivery method results in an
uncontrolled, usually short, diffusion-like release and can
disguise the structure of the metallic implant by applying a
uniform layer to the surface [18]. Whilst this may help to
prevent cell proliferation in stents, in orthopedic applica-
tions it has been shown that a micro/nanostructure is very
important for bone growth, even on the surface of a PLGA
ﬁlm [2]. An alternate method of sustained drug delivery
would be to employ a particulate formulation of PLGA. By
doing so, it would allow for a controlled, tunable drug
release whilst preserving or enhancing the underlying
texture of the implant surface, thus also promoting cellular
interactions.
Titanium and its medical alloys have been the choice for
many years for implanted devices as it displays very good
biocompatibility relative to other metallic biomaterials
such as surgical steel and cobalt–chrome alloys. They are
used in a range of ﬁelds such as dental prostheses, total
joint replacements as well as bone ﬁxation devices [19].
Titanium surfaces can be modiﬁed by various processes
(e.g. plasma spray deposition, sintering, plasma electrolytic
oxidation) to increase the roughness of the titanium surface
or create porous topographies allowing for bone on/in
growth or enhanced cellular interaction [20].
The aim of the work in this paper is to investigate the
morphology and function of a drug eluting metallic porous
surface, produced by the immobilization of PLGA micro-
spheres bearing a drug onto plasma electrolytically oxi-
dized titanium. Research has been performed on these
types of surfaces before, albeit using a ﬁlm or surface-
covering layer to do so [21, 22]. The advantage to using a
particulate drug delivery design would be to allow the
incorporation of sustained drug delivery whilst preserving
the controlled porous topography. The electrolyte chosen
for plasma electrolytic oxidation was calcium acetate and
calcium glycerophosphate, known to introduce calcium and
phosphates in the oxide layers that can act as precursors for
hydroxyapatite formation [23]. The PLGA microspheres
were loaded with dexamethasone, a corticosteroid previ-
ously indentiﬁed with the differentiation of osteoblasts
[24], as a restenosis inhibitor [25] and with the reduction of
inﬂammatory responses [26]. Previous work performed on
these spheres in an unattached, free-in-solution system [27]
has shown that they can act as a sustained dexamethasone
releasing system.
2 Materials and methods
2.1 Materials
Poly (lactide-co-glycolide) (MW: 40,000–75,000, 50:50),
dexamethasone (98%), poly (vinyl alcohol) (MW: 30,000–
70,000), sodium azide, disodium hydrogen phosphate,
sodium dihydrogen phosphate, acetic acid, sodium acetate
and all solvents were purchased from Sigma Aldrich
chemicals. Distilled, deionised water (ddH2O) was provided
from Millipore.
Phosphate buffered saline (PBS) was made up with an
additional 0.1 g/l sodium azide.
2.2 Microspheres synthesis
Following on from our previous work [27], the synthesis of
the spheres can be summarised as follows:
400 mg PLGA and 80 mg dexamethasone were co-dis-
solved in 40 ml dichloromethane:methanol 9:1. This
solution was added in 5 ml fractions to 100 ml 0.2% w/v
PVA solution in ddH2O, and stirred at 1250 rpm for
30 mins, followed by stirring at 60 rpm for 18 h. The
microspheres were then ﬁltered out of solution, washed
with ddH2O, and dried fully in a lyophiliser for 24 h.
2.3 Titanium plasma electrolytic oxidation and sphere
immobilisation
Ti–6Al–7Nb medical alloy (ACNIS International, France)
was used as the substrate in the form of cylindrical disks
with a thickness of 8 mm and a diameter of 19 mm. The
disks were ground with 1,200 grit paper (Struers, Denmark)
using water as lubricating liquid. The samples were ultra-
sonically cleaned, washed in ethanol and deionised water,
then dried under compressed air.
The plasma electrolytic oxidation (PEO) process was
carried out in a double-wall glass electrolytic cell with an
internal volume of 800 ml. The electrolyte used was a
solution of 4.2 g/l calcium glycerophosphate and 24 g/l
calcium acetate in deionised water (Sigma Aldrich).
Titanium disks were suspended in the centre of the
electrolytic cell by screwing them to an insulated metallic
rod acting as an anode whilst a cylindrical steel jacket in
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electrolyte was maintained in the range of 15–25C during
oxidation by water circulation through the cell jacket,
whilst the electrolyte was stirred at a speed of 500 rpm to
maintain homogeneity.
Oxidation was performed under galvanostatic condi-
tions using a current density of 20 A/dm
2 for 5 min,
using an AC (50 Hz) power supply type ACS 1500
(ET Power Systems Ltd, UK). After oxidation, the
samples were thoroughly cleaned with deionised water
and dried in air.
Suspensions of the spheres were made up in ddH2O
with 1 min of sonication at 20 W. Samples of 0.8 ml were
taken from this suspension and dropped onto one face of
the titanium discs as prepared above to form one contin-
uous droplet over the entire surface. This was repeated for
each oxidised and non-oxidised sample. These samples
were placed into an oven (Nabertherm) to allow the water
to evaporate and for the microspheres to bond with the
surface oxide. The thermal treatment applied was opti-
mised around the Tg (45C) of the PLGA used (1 h at
50C).
2.4 Scanning electron microscopy (SEM) and size
analysis
Pictures of the microspheres loaded onto the titanium
samples were obtained using a JEOL 6500 SEM at
5–15 kV. Each sample was gold sputter coated before
analysis, and pictures were taken at 750–10009 magniﬁ-
cation. The images were analysed by Analysis software in
order to produce a size distribution of the bonded spheres
for each sample. At least 150 data points were used to get
an accurate distribution of sizes.
2.5 High performance liquid chromatography (HPLC)
Samples of PBS or acetonitrile (for calibration) had their
dexamethasone concentration analysed by HPLC, and thus
were run on a machine ﬁtted with a reverse phase Varian
Chromosphere C18 column (250 9 4.6 mm) with a run-
ning buffer of 60% acetonitrile, 40% sodium acetate buffer
at pH 4.8. The concentration of dexamethasone was
resolved using a Varian Prostar spectrometer reading at
254 nm, with a dexamethasone peak at 3.75 min. The
machine was calibrated every day of use with at least three
fresh samples of dexamethasone in acetonitrile of known
concentrations straddling the expected concentrations.
2.6 Surface loading efﬁciency
Surface loading efﬁciency (SLE) was calculated using the
following formula:
SLE ¼
drug concentration on surface
maximum expected drug concentration
  100%
A microsphere loaded titanium disc was washed with
approx. 9 g acetonitrile and left to soak in the solvent for
24 h to ensure complete dissolution of all bonded
microspheres. A 1.8 ml sample was analysed by HPLC
as noted in Sect. 2.5 for dexamethasone. Based on this
result the total amount of attached spheres was estimated.
2.7 Release proﬁle assay
Three samples of attached spheres on both oxidised and
non-oxidised titanium discs were incubated in 10 ml PBS
at pH 7.0, 37C with 30 rpm of stirring for 1000 h. Sam-
ples of 1.7 ml were removed and ﬁltered through a 220 nm
polyester membrane to remove any possible detached
PLGA spheres. The incubated sample was then topped up
to 10 ml with fresh, ﬁltered PBS.
Each removed sample was run on an HPLC as described
in Sect. 2.5 with a dexamethasone peak at 3.75 min, and a
peak corresponding to the simulated body ﬂuid at
1.76 min.
3 Results
3.1 Morphology of the immobilised spheres
As found in our previous work [27], the applied micro-
sphere synthesis scheme led to spheres produced of
approximately 20 lm diameter. Typical SEM images of
the spheres attached to oxidised and non-oxidised titanium
are shown in Fig. 1. A slight union between nearby spheres
or partial melting of the spheres (Fig. 1a), showed the
effect of thermal treatment onto the surface. This evidence
suggests that the spheres are lightly attached to the titanium
oxide surface texture. Areas with agglomerated spheres
were occasionally observed. The distribution of sphere
sizes after thermal attachment to the titanium oxide surface
can be seen in Fig. 2. Before thermal treatment, the aver-
age diameter was 20 ± 10 lm[ 27], whilst after thermal
treatment the sphere diameters were found to be
26 ± 10 lm. These overlapping ﬁgures indicate that no
signiﬁcant change in diameter or shape of the spheres
occurred due to thermal treatment.
3.2 Surface loading
The titanium oxide samples prepared in this work were
loaded with approx. 10 mg of the 20 spheres in order to
obtain a monolayer of spheres on each surface. Two
sphere-loaded titanium oxide samples were immersed in
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123acetonitrile in order to assess the resulting dexamethasone
concentration on the surface after thermal treatment, and
thus by using the already known drug loading efﬁciency
(1% [27]), the amount of attached spheres. It was found
that over 80% of the spheres remained attached to the
surface after thermal treatment. Therefore, each 19 mm
diameter disc was loaded with approximately 20 lgo f
dexamethasone.
3.3 In vitro drug release proﬁle
Figure 3 shows the release proﬁle of dexamethasone from
the immobilised PLGA spheres up to 1000 h. It can be seen
that this trend follows the general shape of previous work
on non-attached systems [11, 27]. However, a difference
was observed between the free and immobilised 20 lm
spheres. At the very ﬁrst hour, a dexamethasone release of
over 30% was reached for the attached spheres, whereas
with the non-attached spheres almost no dexamethasone
was released. Additionally, the release rate of both the
attached sphere samples was compared to the non-attached
system after 300 h (80% in 950 h vs. 90% in 550 h). No
signiﬁcant differences have been identiﬁed between the
release proﬁles from the oxidised and non-oxidised loaded
discs.
3.4 Sphere degradation
Figure 4 shows typical SEM images of the immobilised
spheres on porous oxidised titanium after 800 h of in vitro
Fig. 1 Morphology of the immobilized PLGA spheres visualized by
scanning electron microscopy: a 20 lm spheres on an oxidised
titanium surface (15 kV, 91000); b 20 lm spheres on a non-oxidised
titanium surface (5 kV, 91000)
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Fig. 2 Size distribution of the immobilised PLGA spheres. The
values were calculated by visual analysis of the SEM images and
include more than 150 data points
400 800 0 200 600 1000
0
10
20
30
40
50
60
70
80
90
100
110
120
130  Non-attached
 On Oxidised Ti
 On Non-oxidised Ti
C
u
m
u
l
a
t
i
v
e
 
D
e
x
a
m
e
t
h
a
s
o
n
e
 
R
e
l
e
a
s
e
d
 
(
%
)
Time (hours)
Fig. 3 Dexamethasone release proﬁles from the immobilised 20 lm
spheres on non-oxidised and oxidised titanium discs, plus non-
immobilised PLGA spheres (PBS, 37C). Average values with
standard deviations are presented (n = 3)
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123release. The microspheres were deeply eroded, showing
clear diffusion paths for dexamethasone release, as well as
an apparent swelling in the spheres.
4 Discussion
In this study a particulate drug delivery system has been
incorporated into a porous oxidised titanium surface. The
main aim was to assess the feasibility of such a system with
respect to a sustained drug release. It has been shown
before [27] that PLGA spheres of this type show a triphasic
release proﬁle, with a burst, a lag and a linear phase.
The release proﬁles in Fig. 3 show a similar general
trend between the free system and both thermally attached
systems when incubated at 37C in PBS, however a few
changes could be noticed upon closer inspection. The ﬁrst
one is the increase in burst release for the attached systems.
The drug release before 100 h is considered the burst phase
[28]. It is associated with the surface release of drugs, freed
initially by the slow penetration of water into the structure
of the polymer from solution. PLGA reveals a very strong
increase of degradation rate as the incubation temperature
increases [5]. An increase in incubation temperature from
37 to 47C over a period of more than 17 days more than
doubles the rate of polymer degradation. Consequently,
one could consider that during the thermal attachment
process (1 h at 50C) the residual water from deposition
could already begin hydrolysing the polymer, potentially
inducing the observed increase in burst release magnitude
when compared to the free system.
Between approximately 100 and 300 h, the drug release
is almost zero order and can be considered to be in a lag
phase. This period is associated with the continuing
inclusion of water into the polymer structure, but while the
average diffusion path length to solution of a drug mole-
cule is increasing [28]. At this point, the polymer has yet to
break down and result in the later drug release. All three
release proﬁles show this phase, a clear release rate
reduction after 100 h.
After 300 h the release proﬁle changed to a ﬁrst order,
linear phase, associated with the breakdown of the polymer
and release of bioactives from the inner core [28]. SEM
investigation evidenced severe sphere breakdown after
800 h (Fig. 4). The attached microsphere systems show a
lower drug release rate during this phase compared to the
free system, although this is not statistically different. In
these cases it is important to note that the sphere size
distribution does not change, thus this effect comes most
probably from the effects of the attachment process, either
from the thermal treatment, resultant agglomeration, or the
surface itself. Previous experiments with PLGA micro-
spheres have shown that by immobilising spheres onto the
surface of a PLLA nanoﬁbrous scaffold [29], the release
proﬁle of encapsulated drugs is signiﬁcantly slowed. This
is in line with other papers where PLGA spheres are
immobilised in PVA [30]. Thus, immobilising PLGA
microspheres on a metallic surface should also affect the
release rate in the same fashion, through a barrier effect.
The surface could also act to promote agglomeration and
reduce the available surface area for drug release over time.
The morphological difference between oxidised (pore
size 1.1 ± 0.6 lm) and non-oxidised titanium is negligible
when compared to the 20 lm spheres. In addition, the
release proﬁle from the attached system was practically the
same. Thus, it is possible to say that the porosity of
the oxidised titanium surface is sufﬁciently different from
the size of the spheres to not affect the release proﬁle
signiﬁcantly.
The main aim of this investigation was assessing the
feasibility of sustained drug delivery directly from a oxi-
dised titanium disc, while maintaining the topography and
cellular accessibility of the metal surface. The results
shown in this paper indicate that such a surface is possible
to be created with signiﬁcantly longer sustained release
than is typically found for ﬁlms [18], and other porous
surfaces on titanium [21], albeit with issues in the attach-
ment process slightly altering the release proﬁle of the drug
delivery system used.
From the results shown in this study a few applications
for this system can be envisaged, although further work is
needed to reduce agglomeration, enhance sphere attach-
ment, and control the release kinetics. Previous work on
dexamethasone eluting systems for immunosuppression
[26] used 0.5 mg of 20 lm loaded spheres to successfully
reduce inﬂammation around a 1 cm long cotton suture. In
the present study, approximately 10 mg of microspheres
Fig. 4 Morphology of the immobilized PLGA spheres visualized by
scanning electron microscopy after degradation in PBS for 800 h on
an oxidised titanium surface (10 kV, 9750)
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123were used, i.e. 20 times more dexamethasone, although on
an implant signiﬁcantly larger in size. Thus, it can be
considered that this level of loading might be sufﬁcient for
a prolonged anti-inﬂammatory release system from the
surface of a titanium implant. This system can also be
considered for the improvement of bone cell adhesion
(through porosity) as well as for cellular differentiation in
an orthopedic implant as dexamethasone can act as a dif-
ferentiation agent [24, 31].
By using another drug loaded into the PLGA spheres,
it is relatively easy to extend the application range of the
system investigated. Cellular proliferation in tissue scaf-
folds has been researched extensively [29], and such a
delivery system could be applied directly onto the tita-
nium surface, using a morphogenetic protein or a growth
factor.
5 Conclusions
In this study a particulate drug delivery system was loaded
on a oxidised titanium surface with the aim to achieve a
sustained drug release whilst preserving the underlying
morphology. Research into the morphology and function of
this dexamethasone eluting drug delivery system showed
that thermal attachment did not alter the sphere shape and
size dramatically and only had a noticeable effect on drug
release before 100 h. Thus, this system allows the retention
of the porous metallic topography and maintains a sus-
tained release of dexamethasone from the attached 20 lm
spheres for the period of 41 days.
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